anti-her2 therapy for breast cancer ana lilia castruita-avila, m.d.
Published 5 years ago • 443 plays • Length 12:40Download video MP4
Download video MP3
Similar videos
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
51:56
new & supporting data for optimizing therapy in her2 breast cancer | dr. kaklamani and dr. o’regan
-
8:12
her2 breast cancer: neratinib’s role as adjuvant therapy
-
1:03
is there any alternative treatment for breast cancer? - dr. nanda rajaneesh
-
10:05
exploring neoadjuvant therapy for breast cancer: what you need to know
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
1:25
dr. tolaney on the neoadjuvant therapy for her2-positive breast cancer
-
1:41
dr. traina discusses neratinib in her2 breast cancer
-
5:01
neoadjuvant lapatinib in her2 early breast cancer
-
24:07
anti-estrogen therapy for breast cancer
-
9:36
neoadjuvant therapy for hr breast cancer
-
9:35
neratinib in her2 breast cancer
-
3:37
her2 early-stage breast cancer: neoadjuvant strategies
-
1:40
dr. tolaney discusses neratinib in her2 breast cancer
-
2:25
reducing risk in residual breast cancer
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
4:06
will anti-estrogen therapy make me cancer free?
-
3:01
adjuvant endocrine therapy and risk of contralateral breast cancer
-
2:36
identifying breast cancers that are resistant to treatment and reducing resistance.